These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11711296)

  • 1. 6-(4-Benzylpiperazin-1-yl)benzodioxanes as selective ligands at cloned primate dopamine D(4) receptors.
    Hodgetts KJ; Kieltyka A; Brodbeck R; Tran JN; Wasley JW; Thurkauf A
    Bioorg Med Chem; 2001 Dec; 9(12):3207-13. PubMed ID: 11711296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist.
    TenBrink RE; Bergh CL; Duncan JN; Harris DW; Huff RM; Lahti RA; Lawson CF; Lutzke BS; Martin IJ; Rees SA; Schlachter SK; Sih JC; Smith MW
    J Med Chem; 1996 Jun; 39(13):2435-7. PubMed ID: 8691438
    [No Abstract]   [Full Text] [Related]  

  • 3. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationally based efficacy tuning of selective dopamine d4 receptor ligands leading to the complete antagonist 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213).
    Löber S; Hübner H; Utz W; Gmeiner P
    J Med Chem; 2001 Aug; 44(17):2691-4. PubMed ID: 11495580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery of PD 89211 and related compounds: selective dopamine D4 receptor antagonists.
    Pugsley TA; Shih YH; Whetzel SZ; Zoski K; Van Leeuwen D; Akunne H; Mackenzie R; Heffner TG; Wustrow D; Wise LD
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):219-26. PubMed ID: 11817497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1H-Pyrazolo-[3,4-c]cyclophepta[1,2-c]thiophenes: a unique structural class of dopamine D4 selective ligands.
    Thurkauf A; Chen X; Zhang S; Gao Y; Kieltyka A; Wasley JW; Brodbeck R; Greenlee W; Ganguly A; Zhao H
    Bioorg Med Chem Lett; 2003 Sep; 13(17):2921-4. PubMed ID: 14611858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist.
    Dubuffet T; Newman-Tancredi A; Cussac D; Audinot V; Loutz A; Millan MJ; Lavielle G
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2059-64. PubMed ID: 10450981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.
    Patel S; Freedman S; Chapman KL; Emms F; Fletcher AE; Knowles M; Marwood R; Mcallister G; Myers J; Curtis N; Kulagowski JJ; Leeson PD; Ridgill M; Graham M; Matheson S; Rathbone D; Watt AP; Bristow LJ; Rupniak NM; Baskin E; Lynch JJ; Ragan CI
    J Pharmacol Exp Ther; 1997 Nov; 283(2):636-47. PubMed ID: 9353380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
    Vangveravong S; Zhang Z; Taylor M; Bearden M; Xu J; Cui J; Wang W; Luedtke RR; Mach RH
    Bioorg Med Chem; 2011 Jun; 19(11):3502-11. PubMed ID: 21536445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
    Robarge MJ; Husbands SM; Kieltyka A; Brodbeck R; Thurkauf A; Newman AH
    J Med Chem; 2001 Sep; 44(19):3175-86. PubMed ID: 11543687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time analysis of dopamine: antagonist interactions at recombinant human D2long receptor upon modulation of its activation state.
    Pauwels PJ; Tardif S; Wurch T; Colpaert FC
    Br J Pharmacol; 2001 Sep; 134(1):88-97. PubMed ID: 11522600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor.
    Tallman JF; Primus RJ; Brodbeck R; Cornfield L; Meade R; Woodruff K; Ross P; Thurkauf A; Gallager DW
    J Pharmacol Exp Ther; 1997 Aug; 282(2):1011-9. PubMed ID: 9262370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist.
    Enguehard-Gueiffier C; Hübner H; El Hakmaoui A; Allouchi H; Gmeiner P; Argiolas A; Melis MR; Gueiffier A
    J Med Chem; 2006 Jun; 49(13):3938-47. PubMed ID: 16789750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists.
    Glase SA; Akunne HC; Georgic LM; Heffner TG; MacKenzie RG; Manley PJ; Pugsley TA; Wise LD
    J Med Chem; 1997 Jun; 40(12):1771-2. PubMed ID: 9191952
    [No Abstract]   [Full Text] [Related]  

  • 17. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
    J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma S binding via human D2short and D2long dopamine receptors expressed in recombinant cells.
    Gardner B; Hall DA; Strange PG
    Br J Pharmacol; 1996 Jul; 118(6):1544-50. PubMed ID: 8832084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.